Literature DB >> 7660137

The activated megakaryocyte-platelet-system in vascular disease: focus on diabetes.

D Tschoepe1.   

Abstract

Vascular diseases and related complications still represent the main cause of death. In diabetes neuropathy, nephropathy, retinopathy and disturbed nutritive tissue perfusion result from reduced capillary microcirculation. These disturbances are diabetes specific, whereas macroangiopathy does not differ structurally from atherosclerotic lesions of non-diabetic subjects, but leads to accelerated cerebral, coronary and peripheral artery disease. Occurrence of life terminating thrombotic events which are superimposed to those vascular lesions is increased. Thus, morbidity and mortality of diabetes depend mainly on vascular complications. Normal blood flow is a prerequisite of adequate organ perfusion and results from vasomotion, plasma components, corpuscular blood elements, vascular architecture and the undisturbed interaction of these components at the endothelial interface. Functional thromboresistance of the endothelial layer is reduced in the diabetic state. Increased intravascular thrombin generation, reduced fibrinolytic potential and hyperactive platelets lead to a prethrombotic state. This thrombotic diathesis raises the permanent danger of acute flow disruption. Activated platelets operate by three mechanisms: 1. microembolization of the capillaries; 2. local progression of preexisting vascular lesions by secretion of constrictive, mitogenic, and oxidative substances; and 3. trigger of the prognosis limiting arterial thrombotic event. We were able to show that the increased functional properties of diabetic platelets result from the primary release of larger platelets with enhanced thromboxane formation capacity and increased numbers of functional glycoprotein receptors GPIB and GPIIB/IIIA which are synthesized in the megakaryocytes. The megakaryocyte-platelet system is turned on in diabetes mellitus.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7660137     DOI: 10.1055/s-2007-1000390

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  12 in total

1.  Platelet protein damage by free radicals and glycationin vitro: The pathological consequences.

Authors:  K Goswami; B D Bhatla; R Shankar
Journal:  Indian J Clin Biochem       Date:  2000-08

2.  Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions.

Authors:  Tobias Geisler; Karin Mueller; Simon Aichele; Boris Bigalke; Konstantinos Stellos; Patrick Htun; Elena Ninci; Susanne Fateh-Moghadam; Andreas E May; Meinrad Gawaz
Journal:  Clin Res Cardiol       Date:  2010-06-06       Impact factor: 5.460

3.  Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers.

Authors:  M Erdogan; S Solmaz; A Canataroglu; M Kulaksızoglu; S Cetinkalp; A G Ozgen; F Saygili; C Yilmaz
Journal:  Endocrine       Date:  2010-04-14       Impact factor: 3.633

Review 4.  Endothelial Dysfunction and Platelet Hyperactivation in Diabetic Complications Induced by Glycemic Variability.

Authors:  Ye Huang; Long Yue; Jiahuang Qiu; Ming Gao; Sijin Liu; Jingshang Wang
Journal:  Horm Metab Res       Date:  2022-07-14       Impact factor: 2.788

5.  Genetic variation of the platelet- surface integrin GPIIb-IIIa (PIA1/A2-SNP) shows a high association with Type 2 diabetes mellitus.

Authors:  D Tschoepe; B Menart; P Ferber; C Altmann; M Haude; B Haastert; P Roesen
Journal:  Diabetologia       Date:  2003-06-21       Impact factor: 10.122

6.  Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective.

Authors:  Nicholaos Kakouros; Jeffrey J Rade; Antonios Kourliouros; Jon R Resar
Journal:  Int J Endocrinol       Date:  2011-08-21       Impact factor: 3.257

7.  Mean platelet volume and platelet counts in type 2 diabetes: mellitus on treatment and non-diabetic mellitus controls in Lagos, Nigeria.

Authors:  Akinbami Akinsegun; Dada Akinola Olusola; John-Olabode Sarah; Oshinaike Olajumoke; Adediran Adewumi; Odesanya Majeed; Ogbera Anthonia; Uche Ebele; Okunoye Olaitan; Arogundade Olanrewaju; Aile Kingsley
Journal:  Pan Afr Med J       Date:  2014-05-12

8.  Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status.

Authors:  Manling Xie; Zhilei Shan; Yan Zhang; Sijing Chen; Wei Yang; Wei Bao; Ying Rong; Xuefeng Yu; Frank B Hu; Liegang Liu
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

9.  The p48_HPC antithrombogenic flow diverter: initial human experience using single antiplatelet therapy.

Authors:  Pervinder Bhogal; Carlos Bleise; Jorge Chudyk; Ivan Lylyk; Nicolas Perez; Hans Henkes; Pedro Lylyk
Journal:  J Int Med Res       Date:  2019-10-15       Impact factor: 1.671

10.  Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis.

Authors:  Kakali Ghoshal; Maitree Bhattacharyya
Journal:  ScientificWorldJournal       Date:  2014-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.